Antimalarial activity of the myxobacterial macrolide chlorotonil a.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractMyxobacteria are Gram-negative soil-dwelling bacteria belonging to the phylum Proteobacteria. They are a rich source of promising compounds for clinical application, such as epothilones for cancer therapy and several new antibiotics. In the course of a bioactivity screening program of secondary metabolites produced by Sorangium cellulosum strains, the macrolide chlorotonil A was found to exhibit promising antimalarial activity. Subsequently, we evaluated chlorotonil A against Plasmodium falciparum laboratory strains and clinical isolates from Gabon. Chlorotonil A was highly active, with a 50% inhibitory concentration between 4 and 32 nM; additionally, no correlations between the activities of chlorotonil A and artesunate (rho, 0.208) or chloroquine (rho, -0.046) were observed. Per os treatment of Plasmodium berghei-infected mice with four doses of as little as 36 mg of chlorotonil A per kg of body weight led to the suppression of parasitemia with no obvious signs of toxicity. Chlorotonil A acts against all stages of intraerythrocytic parasite development, including ring-stage parasites and stage IV to V gametocytes, and it requires only a very short exposure to the parasite to exert its antimalarial action. Conclusively, chlorotonil A has an exceptional and unprecedented profile of action and represents an urgently required novel antimalarial chemical scaffold. Therefore, we propose it as a lead structure for further development as an antimalarial chemotherapeutic.
CitationAntimalarial activity of the myxobacterial macrolide chlorotonil a. 2014, 58 (11):6378-84 Antimicrob. Agents Chemother.
The following license files are associated with this item:
- In vitro and in vivo properties of ellagic acid in malaria treatment.
- Authors: Soh PN, Witkowski B, Olagnier D, Nicolau ML, Garcia-Alvarez MC, Berry A, Benoit-Vical F
- Issue date: 2009 Mar
- [In vitro susceptibility of P. falciparum isolates from Abidjan (Côte d'Ivoire) to quinine, artesunate and chloroquine].
- Authors: Touré AO, Koné LP, Jambou R, Konan TD, Demba S, Beugre GE, Koné M
- Issue date: 2008 Jan-Mar
- Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon.
- Authors: Kreidenweiss A, Kremsner PG, Mordmüller B
- Issue date: 2008 Sep 24
- Antimalarial activity of Malaria Box Compounds against Plasmodium falciparum clinical isolates.
- Authors: Chirawurah JD, Ansah F, Nyarko PB, Duodu S, Aniweh Y, Awandare GA
- Issue date: 2017 Dec
- Antimalarial activity of endoperoxide compound 6-(1,2,6,7-tetraoxaspiro[7.11]nonadec-4-yl)hexan-1-ol.
- Authors: Sato A, Hiramoto A, Morita M, Matsumoto M, Komich Y, Nakase Y, Tanigawa N, Hiraoka O, Hiramoto K, Hayatsu H, Higaki K, Kawai S, Masuyama A, Nojima M, Wataya Y, Kim HS
- Issue date: 2011 Sep